Related Experiment Video

Updated: Jul 3, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Spironolactone alleviates late cardiac remodeling after left ventricular restoration surgery

Masaki Tsukashita1, Akira Marui, Takeshi Nishina

  • 1Department of Cardiovascular Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. mtsuka@kuhp.kyoto-u.ac.jp

The Journal of Thoracic and Cardiovascular Surgery
|July 8, 2008
PubMed

Insights

Spironolactone effectively prevents cardiac redilation and preserves left ventricular function after left ventricular restoration in rats. This aldosterone blocker alleviates remodeling without causing hypotension, showing promise for treating ischemic cardiomyopathy.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Regenerative Medicine

Background:

  • Left ventricular restoration (LVR) improves function post-ischemic cardiomyopathy but late remodeling can occur.
  • Inhibition of the renin-angiotensin-aldosterone system is known to prevent late remodeling.
  • The effect of spironolactone, an aldosterone blocker, on post-LVR remodeling is not well understood.

Purpose of the Study:

  • To investigate the efficacy of spironolactone in preventing late cardiac remodeling and preserving left ventricular function after LVR.
  • To evaluate the impact of spironolactone on molecular markers of fibrosis and cardiac stress.

Main Methods:

  • Myocardial infarction was induced in rats, followed by LVR surgery.
  • Rats were randomized to receive either vehicle or spironolactone (100 mg/kg/d) post-LVR.
  • Echocardiography, hemodynamic assessment, and molecular analyses (gene expression) were performed.

Main Results:

  • Spironolactone significantly attenuated late cardiac redilation and preserved left ventricular function.
  • Improved systolic and diastolic function, reduced interstitial fibrosis, and decreased TGF-β1 and BNP gene expression were observed.
  • No significant differences in systemic blood pressure or heart rate were noted between groups.

Conclusions:

  • Spironolactone effectively alleviates cardiac remodeling and preserves left ventricular function post-LVR.
  • It reduces key molecular markers of fibrosis and cardiac stress without inducing hypotension.
  • Spironolactone represents a promising therapeutic strategy for managing post-LVR remodeling.
Abstract

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft05:25

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

Published on: September 15, 2023

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.